March 31, 2020

The US Food and Drug Administration (FDA) approved use of blood plasma from recovered patients to treat severely critical COVID-19 patients.


  • It is called convalescent plasma therapy. It seeks to make use of the antibodies developed in the recovered patient against the coronavirus.

  • The whole blood or plasma from such people is taken, and the plasma is then injected in critically ill patients so that the antibodies are transferred and boost their fight against the virus.

  • A COVID-19 patient usually develops primary immunity against the virus in 10-14 days. Therefore, if the plasma is injected at an early stage, it can possibly help fight the virus and prevent severe illness.